Clinical Trial Detail

NCT ID NCT03514069
Title Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

astrocytoma

oligodendroglioma

glioblastoma multiforme

malignant glioma

Therapies

Ruxolitinib

Ruxolitinib + Temozolomide

Age Groups: adult senior

No variant requirements are available.